$JNJ earnings call, on submissions: our bispecific EGFR-cMET in non-small cell lung cancer that will be also #submitted at the end of this year. That also has breakthrough designation.

Moving fast. JNJ already called this a future #blockbuster
#Genmab DuoBody $GMAB #Royalties https://t.co/pHf9g5niFz